Essix Biosciences boosts stake in Ind-Swift Laboratories after amalgamation

On August 27, 2025, Essix Biosciences Limited and its Persons Acting in Concert (PAC) announced a substantial acquisition of 4,515,495 equity shares of Ind-Swift Laboratories Limited. This transaction, executed through a scheme of arrangement for the amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited, represents a 5.53% increase in total share/voting capital and 4.83% of the total diluted share/voting capital.

Before this acquisition, Essix Biosciences Limited held 34.33% of the total share/voting capital. Post-acquisition, the total holding of Essix Biosciences Limited, including its PAC members, reached 32,234,278 shares, representing 39.50% of the total share/voting capital and 34.49% of the total diluted share/voting capital.

The equity share capital of Ind-Swift Laboratories Limited before the acquisition was INR 73,48,68,600, representing 73,486,860 equity shares. After the acquisition, the total equity share capital rose to INR 81,61,15,580, accounting for 81,611,558 equity shares. The total diluted share/voting capital post-acquisition stands at INR 93,46,15,580.